MET and cancer: Genetic mutations of the c-Met receptor have been reported in various cancer types, including papillary renal (20–21), hepatic (22), gastric (23) and pulmonary cancer (24,25), and the overexpression of c-Met has also been reported in numerous cancer tissues (26).